Search Results
Your search for early matches 10131 pages
Showing 9651 - 9700ASCO Releases Annual Report on Progress Against Cancer and Names the Cancer Advance of the Year
ASCO released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, today, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). ASCO credits the improvements in CLL care with the...
CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celator Pharmaceuticals’ investigational agent CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. The FDA established the...
Phase II and III Trials Support First-Line Panitumumab in Combination With FOLFOX in Wild‑Type RAS Metastatic Colorectal Cancer
New data from the phase II PEAK and phase III PRIME studies support the first-line use of panitumumab (Vectibix) in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) in patients with wild-type RAS metastatic colorectal cancer. The study results were presented during a poster session...
Are Physicians Choosing Wisely When Imaging for Distant Metastases in Early-Stage Breast Cancer?
Patients with early-stage breast cancer still undergo imaging for distant metastases despite evidence-based local, national, and international guidelines, and a recommendation from ASCO to avoid such imaging, according to a retrospective review of staging imaging for distant metastases in patients...
Almost Half of Women Taking Tamoxifen for Primary Prevention of Breast Cancer Discontinue Use Before 5 Years
After 4.5 years of taking tamoxifen for primary prevention of breast cancer, 46% of women discontinued use, according to research conducted within the Sister Study, a prospective cohort of women who had a sister who had been diagnosed with breast cancer but did not have breast cancer themselves....
Breast Cancer Diagnoses and Survival Outcomes Vary by Race/Ethnicity
Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biologic differences, according to a study reported by Iqbal et al...
Higher Vitamin D Levels Associated With Markedly Improved Survival in Patients With Advanced Colorectal Cancer
A prospective analysis of data from a phase III study of patients newly diagnosed with metastatic colorectal cancer indicates that patients with higher vitamin D levels have better outcomes after treatment with chemotherapy and targeted therapy. The median overall survival for patients with the...
Adding Ziv-Aflibercept to FOLFIRI Results in Persistent Improvement in Overall Survival in Patients With Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer showed a continued and persistent improvement over time in overall survival when they received ziv-aflibercept (Zaltrap) in addition to FOLFIRI (irinotecan, fluorouracil, leucovorin), reported by Ruff et al in the European Journal of Cancer. Survival was...
No Association of Aromatase Inhibitor–Related Musculoskeletal and Vasomotor Symptoms With Relapse-Free Survival in NCIC CTG MA.27 Analysis
Retrospective analyses of the ATAC, TEAM, and BIG 1-98 adjuvant endocrine therapy trials in breast cancer have suggested that treatment-emergent endocrine symptoms may be associated with superior survival outcomes. In a study reported in the Journal of Clinical Oncology, Stearns et al found no...
Increased Mastectomy Use in Patients With Early-Stage Breast Cancer
In a national retrospective cohort study reported in JAMA Surgery, Kummerow et al found that an increased proportion of women with breast cancer eligible for breast-conserving surgery have undergone mastectomy during recent years. The study involved data from > 1.2 million women with...
Chemotherapy Plus Targeted Therapy Reduces Recurrence in Women With Early-Stage HER2-Positive Breast Cancer
A phase II clinical study of adjuvant paclitaxel and trastuzumab (Herceptin) in women with stage I HER2-positive breast cancer has found the 3-year rate of survival free from invasive disease was 98.7%. The findings may help establish the combination therapy as the first standard treatment approach ...
FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Soligenix’s synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation is reserved for drugs that demonstrate the potential to address an...
Changes in Temporal Patterns and Risk of Recurrence in Breast Cancer Between 1986–1992 and 2004–2008
In a Canadian study reported in Journal of Clinical Oncology, Cossetti and colleagues found that temporal patterns of breast cancer relapse according to estrogen receptor and HER2 status in the period 2004–2008 were similar to those in 1986–1992 but at markedly reduced relapse rates....
More Than 1.5 Million Cancer Deaths Averted During 2 Decades of Dropping Mortality
The American Cancer Society’s annual cancer statistics report found that a 22% drop in cancer mortality over 2 decades led to the avoidance of more than 1.5 million cancer deaths that would have occurred if peak rates had persisted. And while cancer death rates have declined in every state,...
No Overall Survival Difference for Linifanib vs Sorafenib in Advanced Hepatocellular Carcinoma
In a phase III trial reported in the Journal of Clinical Oncology, Cainap et al found that treatment with linifanib, an ATP-competitive inhibitor of VEGF and PDGF receptor tyrosine kinases, did not improve overall survival compared with sorafenib (Nexavar) treatment in patients with advanced...
Postdiagnosis and Pre-/Postdiagnosis Use of Bisphosphonates for Osteoporosis Reduces Risk of Skeletal Metastases in Women With Breast Cancer
In a Canadian study reported in the Journal of the National Cancer Institute, Kremer et al found that postdiagnosis use only or pre-and postdiagnosis use of bisphosphonates for treatment or prevention of osteoporosis in postmenopausal women with breast cancer was associated with a significant...
Bisphosphonates May Help Prevent Endometrial Cancer
A new analysis suggests that women who use bisphosphonates have about half the risk of developing endometrial cancer as women who do not use the drugs. The findings by Alford et al, published early online in Cancer, supports other research that has shown an anticancer effect of this type of...
Targeted Next-Generation Sequencing Reveals a High Number of Genomic Mutations in Advanced Malignant Plural Mesothelioma
Next-generation sequencing in malignant pleural mesothelioma tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival, and cell proliferation pathways, according to a study by Lo Iacono et al in the Journal of Thoracic...
High and Increasing 30-Day Hospital Readmission After Surgery for Advanced Ovarian Cancer in Medicare Population
In a study reported in the Journal of Clinical Oncology, Eskander et al found that rates of 30-day hospital readmission after surgery for advanced ovarian cancer are high and have increased significantly in recent years. In the study, the Surveillance, Epidemiology, and End Results (SEER)-Medicare ...
Hypofractionated Whole-Breast Irradiation After Breast-Conserving Surgery Used in One-Third or Less of Eligible Patients
In a study reported in JAMA, Bekelman et al found that approximately two-thirds of patients with early-stage breast cancer for whom hypofractionated whole-breast irradiation is endorsed receive conventional whole-breast irradiation after breast-conserving surgery. Health-care expenditures were...
Racial Disparities in Colon Cancer Survival Linked to Advanced Disease and Comorbidities at Diagnosis
Racial disparities in colon cancer survival rates may be explained by differences in the health of the patients at diagnosis—both in the stage of the cancer and comorbid conditions—rather than by differences in subsequent treatment, a new study has found. Focusing efforts on prevention...
SABCS 2014: BOLERO-3: Everolimus Plus Trastuzumab/Paclitaxel Misses the Mark in First-Line HER2 Advanced Breast Cancer
The addition of everolimus to weekly trastuzumab (Herceptin) plus paclitaxel did not improve outcomes in the phase III BOLERO-1/TRIO-019, but did provide a “signal” in the hormone receptor–negative subset. The study was reported at the 2014 San Antonio Breast Cancer Symposium by...
SABCS 2014: Lowering Dietary Fat Intake Reduces Death Rates in Some Women With Breast Cancer
Among early-stage breast cancer patients who reduced their dietary fat intake for 5 years following a diagnosis, after over 15 years follow-up, death rates from all causes were significantly reduced in those who had hormone-unrelated breast cancer, according to data from the Women’s...
SABCS 2014: Capecitabine Monotherapy Does Not Improve Survival in Elderly Patients With Early-Stage Breast Cancer
In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, capecitabine, which causes fewer side effects than standard chemotherapy agents, did not improve outcomes when tested as monotherapy, according to data from the phase III...
SABCS 2014: Adding Carboplatin to Neoadjuvant Therapy Increases Pathologic Complete Response Rates Across Subtypes in Triple-Negative Breast Cancer
Among women with triple-negative breast cancer, both basal-like and non–basal-like tumors were equally likely to demonstrate a pathologic complete response to neoadjuvant chemotherapy, but they responded differently to exposure to carboplatin and bevacizumab (Avastin), in an analysis of the...
SABCS 2014: High Tumor Immune Cell Levels May Identify HER2-Positive Breast Cancer Patients Who Might Benefit From Chemotherapy Alone
Women with HER2-positive breast cancer who had high levels of immune cells in their tumors had a decreased risk of cancer recurrence after treatment with chemotherapy alone compared with their counterparts who had low levels of tumor-infiltrating immune cells, according to data presented at the...
SABCS 2014: Pembrolizumab Holds Promise in Breast Cancer, Early Studies Suggest
Single-agent treatment with the immunotherapy drug pembrolizumab (Keytruda) produced a “signal of activity” and led to some durable response, in patients with metastatic triple-negative breast cancer, Rita Nanda, MD, of the University of Chicago, reported at the 2014 San Antonio Breast...
ASH 2014: Pracinostat Combination Shows Significant Clinical Activity in Phase II Study of Newly Diagnosed Acute Myeloid Leukemia
In a phase II study, the histone deacetylase inhibitor pracinostat demonstrated significant clinical activity in combination with azacitadine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Interim data from 33 evaluable patients were presented at the 56th American Society of ...
ASH 2014: T-Cell Acute Lymphoblastic Leukemia Outcomes Excellent, Even for 'Poor-Risk' Group
Outcomes in children with T-cell acute lymphoblastic leukemia (ALL), which has traditionally been considered a poor-prognosis cancer, are better than expected, even for the early thymic precursor (ETP) phenotype, according to investigators from the Children’s Oncology Group (COG) who...
ASH 2014: High Hopes for AG-221 in Advanced Leukemia
Although the data are preliminary, single-agent AG-221 therapy targeted to the IDH2 mutation holds great promise as a nonchemotherapy approach for the treatment of advanced hematologic malignancies, including relapsed/refractory acute myelogenous leukemia (AML) and untreated AML. The findings were...
Daniel F. Hayes, MD, FASCO, Elected ASCO President for 2016-2017 Term
Daniel F. Hayes, MD, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2015. “I'm honored to be elected incoming President of...
CDK7 Inhibitor Effective in Reducing Small Cell Lung Cancer in Preclinical Study
Although small cell lung cancer is an aggressive disease with a high mortality rate, in contrast to other lung carcinomas, there has not been significant progress in the development of therapies for the disease in more than 3 decades. Now, researchers using a high-throughput cellular screen of a...
ASH 2014: Post-Transplant Brentuximab Vedotin Improves Progression-Free Survival in Hodgkin Lymphoma Patients
In Hodgkin lymphoma patients at risk for disease progression following autologous stem cell transplant, early consolidation post-transplant with brentuximab vedotin (Adcetris) significantly improved progression-free survival compared with placebo in the phase III AETHERA trial. The findings were...
Intensified Chemotherapy Based on Tumor Marker Decline May Improve Progression-Free Survival in Patients With Poor-Prognosis Germ Cell Tumors
In the phase III GETUG 13 trial reported in The Lancet Oncology, Fizazi et al found that treatment intensification based on early tumor marker decline resulted in a numeric and borderline statistically significant improvement in progression-free survival in patients with poor-prognosis germ cell...
No Disease-Free Survival Differences Among Doxorubicin/Cyclophosphamide Plus Paclitaxel Regimens in High-Risk Early-Stage Breast Cancer
In the phase III SWOG S0221 trial reported in the Journal of Clinical Oncology, Budd et al found no differences in disease-free survival among four different doxorubicin/cyclophosphamide plus paclitaxel regimens in patients with node-positive or high-risk node-negative breast cancer. A subgroup...
RSNA Awards Gold Medal to Three Leaders in Radiology
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano,...
Risk-Based Screening Misses Over 75% of Invasive Breast Cancers in Women in Their 40s
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer. Results of the study were presented today at RSNA 2014, the annual meeting of the...
Bisphosphonates May Block the Development of HER-Driven Tumors, Preventing Breast, Lung, and Colon Cancers
Two studies have found that bisphosphonates may be effective in preventing certain cancers—including lung, breast, and colon—by blocking abnormal growth signals passed through HER family receptors. The studies suggest that bisphosphonates, the most commonly prescribed medications for...
CONCORD-2 Study Reveals Wide Variability in Global Cancer Survival Rates
As reported in The Lancet by Allemani et al, the CONCORD-2 study of global cancer survival indicates improvements in survival in many countries in colorectal, breast, and prostate cancers, persistent poor outcomes in lung and liver cancers, and wide variability in survival in many cancers. The...
FDG-PET Predicts Complete Response to Neoadjuvant Trastuzumab/Docetaxel in HER2-Positive Breast Cancer
In the French phase II AVATAXHER trial reported in The Lancet Oncology, Coudert et al found that 18F–fluorodeoxyglucose (FDG) positron-emission tomography (PET) predicted complete response to trastuzumab (Herceptin)/docetaxel neoadjuvant therapy and that adding bevacizumab (Avastin) in...
Addition of Vosaroxin to Cytarabine Demonstrates Antileukemic Activity in Relapsed or Refractory Acute Myeloid Leukemia
In a phase Ib/II study of patients with relapsed or refractory acute myeloid leukemia (AML), the addition of vosaroxin to cytarabine demonstrated antileukemic activity and an acceptable risk-benefit profile, according to a study by Lancet et al in Haematologica. Based on the findings from this...
Low Risk of Breast Cancer After Ovarian Cancer in Women With BRCA Mutation
In a retrospective single-institution study reported in JAMA Surgery, Gangi et al found a low risk of breast cancer after diagnosis of ovarian cancer in women harboring BRCA mutations. The study involved 364 women who had BRCA mutation testing for stage I to IV epithelial ovarian...
Adult Survivors of Retinoblastoma Experience Few Cognitive or Social Setbacks
Adult survivors of retinoblastoma, a type of eye cancer that usually develops in early childhood, have few cognitive or social problems decades following their diagnosis and treatment, according to a study by Brinkman et al published in Cancer. The findings offer good news for patients, but the...
Improved Overall Survival in Metastatic Melanoma With First-Line Dabrafenib Plus Trametinib
In a phase III study reported in The New England Journal of Medicine, Robert et al found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) plus the MEK inhibitor trametinib (Mekinist) significantly improved overall survival compared with the BRAF inhibitor vemurafenib (Zelboraf) in...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
Researchers Identify Biomarker of Response to New Ovarian Cancer Drug
Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...
PAM50 Risk of Recurrence Score Helps Predict Late Distant Recurrence After 5 Years of Endocrine Treatment for Breast Cancer
In a combined analysis of outcomes in the translational research cohort of the Arimidex, Tamoxifen Alone or in Combination trial (TransATAC) and the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG 8) trial reported in the Journal of Clinical Oncology, Sestak and colleagues found that the ...
IDH1 Inhibitor Demonstrates Anticancer Activity in Advanced Leukemia
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation. The...
High Rate of Tumor Marker Assessment in Older Early-Stage Breast Cancer Survivors
Current guidelines discourage tumor marker assessment in surveillance of nonmetastatic breast cancer. In a study reported in the Journal of Clinical Oncology, Ramsey et al found that > 40% of Medicare patients with early-stage breast cancer had at least one tumor marker assessment and that...
Interactions Between Genetic Variants and Sun Behaviors May Influence Future Melanoma Risk
The combination of different patterns of sun exposure experienced by children and biomarkers of melanoma risk, such as the number of freckles or moles that develop as a result, may play a large role in future melanoma risk, a study investigating gene and environmental interactions has found....
